Shares of AstraZeneca PLC (LON:AZN – Get Free Report) have earned an average rating of “Moderate Buy” from the nine research firms that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have covered the stock in the last year is £121.57 ($154.47).
Several equities research analysts recently issued reports on the company. Citigroup reiterated a “buy” rating on shares of AstraZeneca in a report on Tuesday, May 28th. Jefferies Financial Group reaffirmed a “hold” rating and set a £113 ($143.58) price target on shares of AstraZeneca in a research report on Tuesday, May 21st. Berenberg Bank upped their price target on AstraZeneca from £130 ($165.18) to £150 ($190.60) and gave the company a “buy” rating in a research report on Friday, June 7th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a £110 ($139.77) price objective on shares of AstraZeneca in a report on Tuesday. Finally, Shore Capital reaffirmed a “buy” rating on shares of AstraZeneca in a report on Tuesday, May 21st.
Read Our Latest Analysis on AZN
AstraZeneca Price Performance
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
See Also
- Five stocks we like better than AstraZeneca
- What Are Trending Stocks? Trending Stocks Explained
- Occidental Stock: Buffett’s 9-Day Buying Spree Lifts Stake to 29%
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- 3M Stock: Invest Now for Unmatched Quality and Growth Potential
- How to Calculate Stock Profit
- Super Micro AI Stock: Should You Invest After a 275% Increase?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.